Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07460947 · ClinicalTrials.gov registry record · Phase 1
A Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder
A Phase 1 study, sponsored by Mclean Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT07460947 is a Phase 1 study that is actively recruiting participants, run by Mclean Hospital. The registered enrollment target is 20 participants.
The verdict
NCT07460947, a Phase 1 study, is actively recruiting participants, sponsored by Mclean Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study tests a new treatment for people with borderline personality disorder (BPD). The treatment combines a medication called D-cycloserine with one day of transcranial magnetic stimulation (TMS). The main questions it aims to answer are: * How many participants complete the treatment? * How do participants feel about the treatment? * Does the treatment have neurophysiological changes on participants? * Does the treatment improve BPD symptoms? * Do the benefits last over time? Participants will be asked to: * Come to the clinic for interviews and testing * Complete weekly questionnaires for 4 weeks before the treatment day * Take D-cycloserine the night before treatment * Attend one treatment day at the clinic. On that day, they may receive up to 20 short TMS sessions (each lasting 3 minutes and separated by 30 minutes). This visit may last up to 12 hours. * Complete weekly questionnaires for 6 weeks after the treatment day.
Interventions
- DEVICE TMS
- DRUG D-Cycloserine (DCS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-06-09 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07460947
The ClinicalTrials.gov registry entry for NCT07460947 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TMS is the first listed.
NCT07460947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07460947 about?
NCT07460947 is a clinical study titled "A Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder". This study tests a new treatment for people with borderline personality disorder (BPD). The treatment combines a medication called D-cycloserine with one day of transcranial magnetic stimulation (TMS). The main questions it aims to answer are: * How many participants complete the treatment? * How ...
What is the current status of trial NCT07460947?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-06-09. Estimated completion is 2027-12.
What interventions are being tested in trial NCT07460947?
The interventions under investigation include: TMS (DEVICE), D-Cycloserine (DCS) (DRUG).
Who is sponsoring clinical trial NCT07460947?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.